A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.

A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.

OBJECTIVE: To determine the current disease-modifying anti-rheumatic drug (DMARD) preferences of UK consultant rheumatologists. METHODS: A questionnaire was sent in May 2002. We asked which DMARD(s) was most frequently preferred first and sought the most typical sequence of DMARDs, including DMARD c...

Полное описание

Библиографические подробности
Главные авторы:	Jobanputra, P, Wilson, J, Douglas, K, Burls, A
Формат:	Journal article
Язык:	English
Опубликовано:	2004

Схожие документы

A SURVEY OF DMARD PREFERENCES OF UK RHEUMATOLOGISTS
по: Douglas, K, и др.
Опубликовано: (2003)

Doctors’ preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment
по: T. Martijn Kuijper, и др.
Опубликовано: (2017-04-01)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
по: Mysler E, и др.
Опубликовано: (2021-06-01)

When the first visit to the rheumatologist is established rheumatoid arthritis
по: Taylor, P, и др.
Опубликовано: (2020)

Myocardial infarction in rheumatoid arthritis: The effects of DMARDs and prednisolone
по: Edwards, C, и др.
Опубликовано: (2008)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
по: Michael D George, и др.
Опубликовано: (2021-04-01)

Periodontal Health as Perceived by Rheumatologists and Rheumatoid Arthritis Patients
по: Natasha Proud, и др.
Опубликовано: (2023-04-01)

DIAGNOSTIC MARKERS AND CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING DMARDS
по: Maria Sergeevna Voronina, и др.
Опубликовано: (2012-10-01)

Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis
по: Kai Wei, и др.
Опубликовано: (2022-03-01)

Clinical evaluation of DMARDs and NSAIDs in cases of Rheumatoid arthritis in Chhattisgarh
по: Basant Kumar Maheshwari
Опубликовано: (2018-01-01)

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: A systematic review and economic evaluation
по: Jobanputra, P, и др.
Опубликовано: (2002)

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.
по: Jobanputra, P, и др.
Опубликовано: (2002)

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation
по: P. Jobanputra, и др.
Опубликовано: (2002-01-01)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
по: Juthamas Prawjaeng, и др.
Опубликовано: (2023-05-01)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
по: Barton, P, и др.
Опубликовано: (2004)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
по: Barton, P, и др.
Опубликовано: (2004)

A 4-year non-randomized comparative phase-IV study of early rheumatoid arthritis: integrative anthroposophic medicine for patients with preference against DMARDs versus conventional therapy including DMARDs for patients without preference
по: Hamre HJ, и др.
Опубликовано: (2018-03-01)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis
по: P Barton, и др.
Опубликовано: (2004-03-01)

Elderly-onset rheumatoid arthritis: an outlook from a practicing rheumatologist
по: Ch. Baimukhamedov
Опубликовано: (2020-09-01)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis - Introduction
по: Barton, P, и др.
Опубликовано: (2004)

Patients’ and rheumatologists’ perceptions on preventive intervention in rheumatoid arthritis and axial spondyloarthritis
по: Laurette van Boheemen, и др.
Опубликовано: (2020-09-01)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis
по: Clark, W, и др.
Опубликовано: (2004)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
по: Clark, W, и др.
Опубликовано: (2004)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
по: Clark, W, и др.
Опубликовано: (2004)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis
по: W Clark, и др.
Опубликовано: (2004-09-01)

Individual DMARDs have different effects on the likelihood of developing septic arthritis in adults with rheumatoid arthritis
по: Edwards, C, и др.
Опубликовано: (2005)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
по: James Cheng-Chung Wei, и др.
Опубликовано: (2023-07-01)

Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion
по: Emiliano Marasco, и др.
Опубликовано: (2023-09-01)

Safety and efficacy of newer biologics DMARDs in the management of rheumatoid arthritis: A systematic review
по: Basiru Ahmad Zago, и др.
Опубликовано: (2020-12-01)

Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope
по: Tillett, W, и др.
Опубликовано: (2020)

Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients
по: Hazan Karadeniz, и др.
Опубликовано: (2022-04-01)

The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
по: Soo-Kyung Cho, и др.
Опубликовано: (2017-12-01)

Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis
по: Esteban A. Gomez, и др.
Опубликовано: (2020-10-01)

Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study
по: Seogsong Jeong, и др.
Опубликовано: (2022-07-01)

Challenges in implementing treat-to-target in rheumatoid arthritis: a perspective from Brazilian rheumatologists
по: Adriana Maria Kakehasi, и др.
Опубликовано: (2024-08-01)

Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making
по: Bolge SC, и др.
Опубликовано: (2016-06-01)

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
по: Ruiz Garcia, V, и др.
Опубликовано: (2014)

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
по: Ruiz Garcia, V, и др.
Опубликовано: (2011)

To flare or not to flare: patients’ and rheumatologists’ perceptions on the on-flare retreatment strategy of rituximab in rheumatoid arthritis
по: Delphine Bertrand, и др.
Опубликовано: (2024-02-01)

The use of methotrexate in rheumatoid arthritis. Recommendations of the All-Russian public organization “Association of Rheumatologists of Russia”
по: E. L. Nasonov, и др.
Опубликовано: (2023-08-01)